News

Green light for stem cell study
Enlarge image

Clinical TrialsUK

Green light for stem cell study

15.08.2012 - The British stem cell specialist ReNeuron has received the go-ahead for its phase I trial with disabled stroke patients.

After having reviewed the safety data from the first two dose cohorts, the Data Safety Monitoring Board (DSMB) has recommended to continue the PISCES trial with ReN001. ReNeuron’s ReN001 cell therapy for stroke consists of a neural stem cell line. Until now, no adverse side effects have been found in the review period. Six patients have been included in the trial, the first 18 months ago. “We are delighted that the DSMB have given a favourable recommendation to proceed to the higher and penultimate dose in the PISCES stroke trial,” said ReNeuron’s chief executive Michael Hunt. The study is testing the safety and tolerability of the treatment of ascending doses of the ReN001 cells in patients with moderate to severe functional neurological impairments from their strokes in what is the world’s first fully regulated clinical trial. In June this year, the firm revealed that the first five PISCES patients showed reductions in neurological impairment and spasticity. These improvements were sustained in the longer-term. If everything goes on as planned, ReNeuron could apply for a phase II study in 2013.

http://www.european-biotechnology-news.com/news/news/2012-03/green-light-for-stem-cell-study.html

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)9.85 SEK15.20%
  • ZEALAND PHARMA (DK)158.00 DKK12.86%
  • ERYTECH PHARMA (F)36.51 EUR6.13%

FLOP

  • FLAMEL TECHNOLOGIES (F)23.00 USD-10.47%
  • ZELTIA (E)3.69 EUR-8.44%
  • WILEX (D)3.28 EUR-6.29%

TOP

  • IXICO (UK)35.00 GBP55.6%
  • DBV TECHNOLOGIES (F)79.73 EUR53.7%
  • ZEALAND PHARMA (DK)158.00 DKK43.0%

FLOP

  • BIOTEST (D)25.73 EUR-63.2%
  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • BIOTECH PHARMACON (N)9.47 NOK-44.9%

TOP

  • ADOCIA (F)90.49 EUR580.9%
  • FORMYCON (D)28.68 EUR323.6%
  • DBV TECHNOLOGIES (F)79.73 EUR309.1%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-70.3%
  • NEOVACS (F)1.02 EUR-69.1%

No liability assumed, Date: 30.07.2015